Lercanidipine hydrochloride
- CAS No.
- 132866-11-6
- Chemical Name:
- Lercanidipine hydrochloride
- Synonyms
- LERCANIDIPINE HCL;Lercanidipine hydrochloride heMihydrate;CLAP;mE10;R 75;BCL10;c-E10;CIPER;IMD37;CarMen
- CBNumber:
- CB0371085
- Molecular Formula:
- C36H42ClN3O6
- Molecular Weight:
- 648.19
- MDL Number:
- MFCD07773089
- MOL File:
- 132866-11-6.mol
- MSDS File:
- SDS
- TDS File:
- TDS
| Melting point | 175-177°C |
|---|---|
| storage temp. | 2-8°C |
| solubility | soluble in Methanol |
| form | powder |
| color | yellow |
| Merck | 14,5446 |
| InChIKey | WMFYOYKPJLRMJI-UHFFFAOYSA-N |
| SMILES | C1(C)NC(C)=C(C(OC(C)(C)CN(CCC(C2=CC=CC=C2)C2=CC=CC=C2)C)=O)C(C2=CC=CC([N+]([O-])=O)=C2)C=1C(OC)=O.[H]Cl |
| CAS DataBase Reference | 132866-11-6(CAS DataBase Reference) |
| FDA UNII | OA8TFX68PE |
| UNSPSC Code | 12352200 |
| NACRES | NA.77 |
SAFETY
Risk and Safety Statements
| Symbol(GHS) | ![]() GHS06 |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Signal word | Danger | |||||||||
| Hazard statements | H301 | |||||||||
| Precautionary statements | P301+P310 | |||||||||
| PPE | Eyeshields, Faceshields, Gloves, type P2 (EN 143) respirator cartridges | |||||||||
| Hazard Codes | T | |||||||||
| Risk Statements | 25 | |||||||||
| Safety Statements | 36/37-45 | |||||||||
| RIDADR | UN 2811 | |||||||||
| WGK Germany | 3 | |||||||||
| HS Code | 2933.39.4100 | |||||||||
| Storage Class | 6.1C - Combustible acute toxic Cat.3 toxic compounds or compounds which causing chronic effects |
|||||||||
| Hazard Classifications | Acute Tox. 3 Oral | |||||||||
| Toxicity | LD50 in mice (mg/kg): 83 i.p.; 657 orally (Nardi) | |||||||||
| NFPA 704 |
|
Lercanidipine hydrochloride price More Price(96)
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Sigma-Aldrich | L6668 | Lercanidipine hydrochloride ≥98% (HPLC) | 132866-11-6 | 10mg | $225 | 2026-04-30 | Buy |
| Sigma-Aldrich | L6668 | Lercanidipine hydrochloride ≥98% (HPLC) | 132866-11-6 | 50mg | $638 | 2026-04-30 | Buy |
| TCI Chemical | L0282 | Lercanidipine Hydrochloride >98.0%(HPLC)(T) | 132866-11-6 | 200mg | $18 | 2026-04-30 | Buy |
| TCI Chemical | L0282 | Lercanidipine Hydrochloride >98.0%(HPLC)(T) | 132866-11-6 | 1g | $37 | 2026-04-30 | Buy |
| Cayman Chemical | 29104 | Lercanidipine (hydrochloride) ≥98% | 132866-11-6 | 50mg | $42 | 2026-04-30 | Buy |
Lercanidipine hydrochloride Chemical Properties, Uses, Production
Chemical Properties
Pale-Yellow Powder
Uses
A dihydropyridine calcium channel blocker. Antihypertensive.
Uses
long-acting dihydropyridine calcium channel blocker, antihypertensive
Definition
ChEBI: Lercanidipine hydrochloride is a diarylmethane.
brand name
Cardiovasc (Recor dati, Italy); Carmen (Recordati, Italy); Corifeo (Recordati, Italy); Lercadip (Recordati, Italy); Lercan (Recordati, Italy); Lercapin (Recordati, Italy); Lercaton (Recordati, Italy); Lerkamen (Recordati, Italy); Lerzam (Recordati, Italy); Renovia (Recordati, Italy); Vasodip (Recordati, Italy); Zandip (Recordati, Italy); Zanicor (Recordati, Italy).
Biological Activity
L-type Ca 2+ channel blocker that displays higher vascular selectivity than Felodipine (4-(2,3-Dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid ethyl methyl ester ). Causes peripheral vasodilation with only weak negative inotropic activity. Antihypertensive.
Biochem/physiol Actions
Lercanidipine hydrochloride is a L-type (Cav1.2b) vascular channel antagonist; L-type (Cav1.2a) cardiac channel agonist voltage-dependent and highly lipophylic compound, which exhibits a slower onset and longer duration of action than other calcium channel antagonists; an antihypertensive agent in patients with mild-to-moderate hypertension; more vasoselective than lacidipine and amlodipine.
Synthesis
957215-03-1
132866-11-6
The general procedure for the synthesis of 3-(1-((3,3-diphenylpropyl)(methyl)amino)-2-methylpropan-2-yl)5-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate hydrochloride from the compound (CAS:957215-03-1) is as follows: 10 mmol of oxalate salt (Example 4) was dissolved in 100 mL of dichloromethane and 20 mL of aqueous solution containing 20 mmol of potassium carbonate was added. The organic phase was separated and the aqueous phase was extracted with 2 x 10 mL of dichloromethane. The organic phase was combined and treated with 20 mL of 1N hydrochloric acid solution. The organic phase was separated and concentrated. The residue was dissolved in 2,000 mL of water and 2 mL of 1N hydrochloric acid and 5 mL of saturated aqueous sodium chloride were added to form I hydrochloride hemihydrate and the product was collected by filtration. Yield: 6.2 g (95%); Purity: 99.8% (HPLC); Melting point: 118-122 ° C. HPLC conditions: RP 16 column, 125×3 mm ID, 5 μm, Detection wavelength: 233 nm; Eluent composition: 0.01 mol Na2HPO4/MeOH/acetonitrile=25/65/10; Retention time: about 15 min.
Description
BCL10 Human Recombinant produced in E. coli is a single polypeptide chain containing 257 amino acids (1-233) and having a molecular mass of 28.8kDa (molecular weight on SDS-PAGE will appear higher).
BCL10 is fused to a 24 amino acid His-tag at N-terminus & purified by proprietary chromatographic techniques.
Source
Ecoli
Background
BCL10 holds a caspase recruitment domain (CARD), and is known as an inducer of apoptosis and as NF-kappaB activator. BCL10 cooperates with other CARD domain containing proteins such as CARD9, 10, 11 and 14, which operates as upstream regulators in NF-kappaB signaling. BCL10 is known to create a complex with MALT1, a protein encoded by another gene and is translocated in MALT lymphoma. MALT1 and BCL10 protein synergize the activation of NF-kappaB, and the deregulation of either of them facilitates the same pathogenetic process which leads to the malignancy.
References
[1] Patent: EP1860102, 2007, A1. Location in patent: Page/Page column 1; 8; 15
Lercanidipine hydrochloride Preparation Products And Raw materials
Raw materials
1of2
Preparation Products
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| Nanjing Machido Pharmaceutical Technology Co., Ltd. | 19556085883 | sales@machidopharma.com | China | 393 | 58 |
| Hefei Qiming Pharmaceutical Technology Co., Ltd | 15105695099 | 123642210@qq.com | China | 929 | 58 |
| Suzhou Yuanhuan Pharmaceutical Technology Co., Ltd. | 0512-18136053398 18136053398 | 2982784935@qq.com | China | 80 | 58 |
| Suzhou lipin Chemical Co., Ltd | 0512-67509664 19888480046 | 3516936381@qq.com | China | 111 | 58 |
| J & K SCIENTIFIC LTD. | 18210857532 18210857532 | jkinfo@jkchemical.com | China | 96815 | 76 |
| 3B Pharmachem (Wuhan) International Co.,Ltd. | 18930552037 | 3bsc@sina.com | China | 15813 | 69 |
| future industrial shanghai co., ltd | 400-0066400 13621662912 | sales@jonln.com | China | 1989 | 65 |
| Chembest Research Laboratories Limited | 021-20908456 | sales@BioChemBest.com | China | 5996 | 61 |
| JinYan Chemicals(ShangHai) Co.,Ltd. | 13817811078 | sales@jingyan-chemical.com | China | 9963 | 60 |
| Adamas Reagent, Ltd. | 400-6009262 15618770481 | yhx@titansci.com | China | 14098 | 59 |
View Latest Price from Lercanidipine hydrochloride manufacturers
| Image | Update time | Product | Price | Min. Order | Purity | Supply Ability | Manufacturer | |
|---|---|---|---|---|---|---|---|---|
![]() |
2026-09-17 | Lercanidipine hydrochloride
132866-11-6
|
0.99 | RongNa Biotechnology Co.,Ltd | ||||
![]() |
2026-09-17 | Lercanidipine hydrochloride
132866-11-6
|
1KG | 99% | 1000KG | Hangzhou Hyper Chemicals Limited | ||
![]() |
2026-07-27 | Lercanidipine hydrochloride
132866-11-6
|
$29.00-176.00 | 99.91% | 10g | TargetMol Chemicals Inc. |
-

- Lercanidipine hydrochloride
132866-11-6
- 0.99
- RongNa Biotechnology Co.,Ltd
-

- Lercanidipine hydrochloride
132866-11-6
- 99%
- Hangzhou Hyper Chemicals Limited
-

- Lercanidipine hydrochloride
132866-11-6
- $29.00-176.00
- 99.91%
- TargetMol Chemicals Inc.
132866-11-6 (Lercanidipine hydrochloride) Related Search:
1of4






